Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Instil Bio, Inc.NASDAQ: TIL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$2.64M, compared with -$26.82M a year earlier. Trailing-twelve-month EBITDA was -$41.59M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -4.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.64M+64.3% QoQ
- Last fiscal yearDec 2025
- -$65.01M-4.0% YoY
- LTMMar 2026
- -$41.59M+38.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +90.2% | +100.0% | +9.8 pp |
| 1 year | -4.0% | +100.0% | +104.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (65.01M) USD
- Year-over-year change
- -4.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (65.01M) | -4.0% |
| FY2024 | 2024-12-31 | (62.53M) | +57.5% |
| FY2023 | 2023-12-31 | (147.12M) | +32.3% |
| FY2022 | 2022-12-31 | (217.38M) | -42.5% |
| FY2021 | 2021-12-31 | (152.51M) | — |
EBITDA vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +38.3% is the 2nd highest of 9, against a peer median of -2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -CA$36.08M CAD | -19.5% | — | — | |
| LTM Mar 2026 | -$41.59M USD | +38.3% | — | — | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$107.98M USD | +49.6% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M USD | -490.7% | — | — |
| LTM Mar 2026 | -$130.98M USD | +37.9% | — | — | |
| LTM Mar 2026 | -$342.25M USD | -325.9% | — | 4567.0% | |
| Peer median (excluding TIL) | — | -2.7% | — | 4595.1% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 5.99M | 0 | 0 | 534K |
| Gross Profit | 0 | (5.99M) | 0 | 0 | (534K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 107.25M | 141.06M | 39.6M | 11.84M | 10M |
| Selling, General & Admin | 51.31M | 62.24M | 47.55M | 44.21M | 27.22M |
| Operating Expenses | 155.56M | 200.18M | 159.17M | 73.54M | 52.37M |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| EBITDA | (152.51M) | (217.38M) | (147.12M) | (62.53M) | (65.01M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (155.56M) | (206.17M) | (159.17M) | (73.54M) | (52.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 80K | 3.66M | 8.87M | 6.99M | 3.86M |
| Interest Expense | 0 | 1.88M | 5.21M | 8.99M | 5.83M |
| Other Income / Expenses | (1.2M) | (19.08M) | 3.08M | (594K) | (18.47M) |
| Income Before Tax | (156.76M) | (225.25M) | (156.09M) | (74.14M) | (71.37M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39K | (2.07M) | 0 | 0 | 0 |
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| EPS (Diluted) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| Weighted Avg Shares | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
| Weighted Avg Shares (Diluted) | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.